RPL17 and adult T-cell leukemia/lymphoma: Existing evidence strongly suggests ICIs carry a significant risk of inducing HPD in specific T-cell lymphomas (particularly Adult T-cell Leukemia/Lymphoma (ATLL)-inactive subtype), potentially due to the PD-1 pathway’s unique “tumor-suppressive” function in these cancers (93).